SABS SAB Biotherapeutics, Inc.

Nasdaq sabbiotherapeutics.com


$ 2.94 $ 0.49 (19.52 %)    

Monday, 20-Oct-2025 17:15:48 EDT
QQQ $ 611.89 $ 7.61 (1.26 %)
DIA $ 467.41 $ 5.24 (1.13 %)
SPY $ 671.66 $ 6.91 (1.04 %)
TLT $ 91.65 $ 0.35 (0.38 %)
GLD $ 401.70 $ 14.16 (3.64 %)
$ 3
$ 2.59
$ 2.40 x 64
$ 3.03 x 2,536
$ 2.57 - $ 3.05
$ 1.00 - $ 6.60
851,519
na
31.23M
$ 1.38
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 03-28-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-20-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-21-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 04-14-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-29-2022 12-31-2021 10-K
16 11-22-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-21-2021 03-31-2021 10-Q
19 04-02-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 chardan-capital-maintains-buy-on-sab-biotherapeutics-maintains-12-price-target

Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $12 price target.

 leerink-partners-initiates-coverage-on-sab-biotherapeutics-with-outperform-rating-announces-price-target-of-7

Leerink Partners initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Outperform rating and announces Price Target ...

 sab-biotherapeutics-to-present-at-the-61st-annual-meeting-of-the-european-association-for-the-study-of-diabetes-easd-being-held-september-15--19-2025-at-the-viecon---vienna-congress--convention-center-in-vienna-austria

MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB BIO" or the "Company"...

 chardan-capital-maintains-buy-on-sab-biotherapeutics-lowers-price-target-to-12

Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $...

 hc-wainwright--co-maintains-buy-on-sab-biotherapeutics-lowers-price-target-to-9

HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price tar...

 sab-bio-raises-175m-in-oversubscribed-private-placement-to-fully-fund-phase-2b-safeguard-trial-for-autoimmune-type-1-diabetes

Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, ...

 chardan-capital-maintains-buy-on-sab-biotherapeutics-maintains-20-price-target

Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $20 price target.

 hc-wainwright--co-assumes-sab-biotherapeutics-at-buy-announces-price-target-of-10

HC Wainwright & Co. analyst Emily Bodnar assumes SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION